Thorne Healthtech, Inc.
BioSniper Score
4-factor signal
Market Cap
—
Cash Runway
7.9 mo
Lead Asset
collagen plus (Approved)
Next Catalyst
—
Thorne Healthtech, Inc.: 3 pipeline candidates · Updated within the last hour.
Go deeper on Thorne Healthtech, Inc. with Spotter
Ask follow-up questions and run a full multi-agent deep dive on THRN — live, with citations.
Score breakdown4-factor signal · derived from public data
7.9 months
D/E 0.83 · 0% dilution
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Key Financialsas of June 30, 2023
Cash
$32.3M
Quarterly Burn
$24.0M
Revenue
$72.7M
Free Cash Flow
$15.0M
Total Liabilities
$127.3M
Shareholders Equity
$153.8M
Current Ratio
2.41
Commercialization & Governance
Commercialization
- Status
- Commercial
- Has Revenue
- Yes
Governance
- Board Size
- 7
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| collagen plus | Approved |
| metabolic health | Approved |
| niacel | Preclinical |
Frequently asked questions
What is Thorne Healthtech, Inc.'s lead drug candidate?
Thorne Healthtech, Inc.'s most advanced tracked candidate is collagen plus (Approved) for combat the physical signs of aging.
Who is the CEO of Thorne Healthtech, Inc.?
Contents Thorne Health is the chief executive officer of Thorne Healthtech, Inc. (THRN).
What therapeutic areas does Thorne Healthtech, Inc. focus on?
Thorne Healthtech, Inc. develops therapies across Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on Thorne Healthtech, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.